+ |
JARID2 | down-regulates quantity by repression
transcriptional regulation
|
MYOG |
0.2 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-249599 |
|
|
Homo sapiens |
Rhabdomyosarcoma Cell Line |
pmid |
sentence |
23435416 |
JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells|Addition of Differentiation Media (DM) to human myoblasts was associated with the induction of MYOG, MYOD and MYL1 and a decrease in JARID2 RNA expression|Furthermore, we that showed JARID2 binds to and alters the methylation status of histone H3 lysine 27 in the promoter regions of MYOG and MYL1 and that the interaction of JARID2 at these promoters is dependent upon EED, a core component of the Polycomb Repressive Complex 2 (PRC2). Therefore JARID2 is a downstream effector of PAX3-FOXO1 that maintains an undifferentiated myogenic phenotype that is characteristic of RMS |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
PAX7-FOXO1 | up-regulates quantity by expression
transcriptional regulation
|
JARID2 |
0.2 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-249597 |
|
|
Homo sapiens |
|
pmid |
sentence |
23435416 |
JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells| we demonstrated that JARID2 is a direct transcriptional target of the PAX3-FOXO1 fusion protein.| Therefore, JARID2 is a downstream effector of PAX3-FOXO1 that maintains an undifferentiated myogenic phenotype that is characteristic of RMS |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
miR-155 | down-regulates quantity by repression
post transcriptional regulation
|
JARID2 |
0.4 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-269188 |
|
|
Homo sapiens |
|
pmid |
sentence |
31390932 |
Mechanically, LINC01133 functioning as a ceRNA targeted miR-4784 to augment AHDC1 expression. Finally, LINCO1133/miR-4784 aggravated the malignant growth and aggressiveness and EMT of cervical cancer in an AHDC1-dependant way. In conclusion, we unveiled that LINC01133 may function as a ceRNA for miR-4784 to advance AHDC1 expression, intensifying CC cell malignant phenotypes and EMT process, which may demonstrate the implied value of LINC01133 as a therapeutic target for CC patients. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
JARID2 | down-regulates quantity by repression
transcriptional regulation
|
NPPA |
0.2 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-224790 |
|
|
Rattus norvegicus |
Cardiomyocyte Cell Line |
pmid |
sentence |
15542826 |
JMJ physically associates with Nkx2.5 and GATA4 in vitro and in vivo as determined by glutathione S-transferase pull-down and immunoprecipitation assays. we show that JMJ represses ANF gene expression by inhibiting transcriptional activities of Nkx2.5 and GATA4. |
|
Publications: |
1 |
Organism: |
Rattus Norvegicus |
+ |
JARID2 | down-regulates activity
binding
|
GATA4 |
0.468 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-224697 |
|
|
Rattus norvegicus |
Cardiomyocyte Cell Line |
pmid |
sentence |
15542826 |
JMJ physically associates with Nkx2.5 and GATA4 in vitro and in vivo as determined by glutathione S-transferase pull-down and immunoprecipitation assays. we show that JMJ represses ANF gene expression by inhibiting transcriptional activities of Nkx2.5 and GATA4. |
|
Publications: |
1 |
Organism: |
Rattus Norvegicus |
+ |
JARID2 | down-regulates activity
binding
|
NKX2-5 |
0.467 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-224787 |
|
|
Rattus norvegicus |
Cardiomyocyte Cell Line |
pmid |
sentence |
15542826 |
JMJ physically associates with Nkx2.5 and GATA4 in vitro and in vivo as determined by glutathione S-transferase pull-down and immunoprecipitation assays. we show that JMJ represses ANF gene expression by inhibiting transcriptional activities of Nkx2.5 and GATA4. |
|
Publications: |
1 |
Organism: |
Rattus Norvegicus |